Ondansetrón Qualigen (Ondansetron)

Ondansetron is employed across several clinical pathways that involve emesis control.

• Chemotherapy‑induced nausea and vomiting (CINV): helps reduce the frequency and severity of nausea and vomiting in patients receiving cytotoxic cancer therapy.
• Radiotherapy‑induced nausea and vomiting (RINV): provides prophylactic relief for patients undergoing radiation treatment.
• Post‑operative nausea and vomiting (PONV): decreases the incidence of nausea and vomiting after surgical procedures.
• Hyperemesis gravidarum (severe pregnancy‑related nausea): used under specialist supervision to control persistent vomiting when other measures fail.

• Ondansetron selectively blocks serotonin (5‑HT3) receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents the initiation of the vomiting reflex triggered by chemotherapeutic agents, radiation, or surgical stress.

Adverse reactions to ondansetron are generally mild, but clinicians monitor both common and rare events.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel motility.
• Diarrhoea: occasional loose stools.
• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: transient light‑headedness.
• Injection site pain (if administered parenterally).

Serious or Rare Side Effects

• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe hypersensitivity: rash, itching, swelling, or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes.
• Vision changes: blurred vision or visual disturbances.
• Neuroleptic malignant‑like syndrome: extremely rare neurological emergency.

When prescribing ondansetron, consider the following safety measures:

• Cardiac monitoring: avoid in patients with known prolonged QT or electrolyte disturbances.
• Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use.
• Concomitant serotonergic drugs: assess risk of serotonin syndrome.
• Liver impairment: dose adjustment may be required in moderate to severe hepatic disease.
• Pregnancy and lactation: use only if clearly needed, after risk‑benefit evaluation.
• Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Ondansetron can interact with several medication classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Class I anti‑arrhythmics (e.g., quinidine, procainamide): additive QT‑prolongation risk.
• Certain antipsychotics (e.g., haloperidol, ziprasidone): combined effect on cardiac repolarisation.
• Serotonergic agents (e.g., tramadol, linezolid): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase ondansetron plasma levels.
• CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration of their metabolism.
• Oral contraceptives: rare reports of reduced efficacy, monitor cycle control.